Kala Bio (KALA) EPS (Basic) (2016 - 2026)

Kala Bio (KALA) posted EPS (Basic) of -$0.15 for Q1 2026, down 103.46% sequentially from $4.21 in Q4 2025, and up 99.79% YoY from -$0.07 in Q1 2025.

Kala Bio (KALA) EPS (Basic) (2016 - 2026) Analysis & Trends

Kala Bio has reported EPS (Basic) for 11 years, with the latest figure at -$0.15 in Q1 2026.

Quarterly EPS (Basic) rose 99.79% year-over-year to -$0.15 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.66 (up 99.41% YoY) and the FY2025 annual result came in at -$165.56, up 67.36% from the prior year.
EPS (Basic) eased to -$0.15 in Q1 2026 per KALA's latest filing, from $4.21 in the prior quarter.
Over five years, EPS (Basic) peaked at $969.75 in Q3 2022 and troughed at -$1118.3 in Q1 2022.
A 5-year average of -$189.3 and a median of -$158.06 in 2024 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2023: EPS (Basic) jumped 189.71% in 2022, then sank 117.6% in 2023.
Over 5 years, EPS (Basic) stood at -$422.3 in 2022, then surged by 58.0% to -$177.36 in 2023, then surged by 39.29% to -$107.68 in 2024, then jumped by 103.91% to $4.21 in 2025, then sank by 103.46% to -$0.15 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.15, $4.21, and -$53.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	12.62
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	7.59
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.23
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-0.72
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.18
10	Kala Bio	9.89 Mn	9.89 Mn	-	-0.15

Download Data